Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning.

Chaudhury S, Duncan EH, Atre T, Storme CK, Beck K, Kaba SA, Lanar DE, Bergmann-Leitner ES.

Sci Rep. 2018 Nov 30;8(1):17508. doi: 10.1038/s41598-018-35452-x.

2.

Author Correction: A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Thomson-Luque R, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather N, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.

Nat Commun. 2018 Jun 8;9(1):2317. doi: 10.1038/s41467-018-04817-1.

3.

A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.

Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Thomson-Luque R, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather N, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.

Nat Commun. 2018 May 9;9(1):1837. doi: 10.1038/s41467-018-04221-9. Erratum in: Nat Commun. 2018 Jun 8;9(1):2317.

4.

Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.

Beck Z, Torres OB, Matyas GR, Lanar DE, Alving CR.

J Control Release. 2018 Apr 10;275:12-19. doi: 10.1016/j.jconrel.2018.02.006. Epub 2018 Feb 9.

5.

Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine.

Kaba SA, Karch CP, Seth L, Ferlez KMB, Storme CK, Pesavento DM, Laughlin PY, Bergmann-Leitner ES, Burkhard P, Lanar DE.

Vaccine. 2018 Feb 1;36(6):906-914. doi: 10.1016/j.vaccine.2017.12.001. Epub 2017 Dec 29.

6.

Protein nanovaccine confers robust immunity against Toxoplasma.

El Bissati K, Zhou Y, Paulillo SM, Raman SK, Karch CP, Roberts CW, Lanar DE, Reed S, Fox C, Carter D, Alexander J, Sette A, Sidney J, Lorenzi H, Begeman IJ, Burkhard P, McLeod R.

NPJ Vaccines. 2017 Sep 5;2:24. doi: 10.1038/s41541-017-0024-6. eCollection 2017.

7.

The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.

Karch CP, Doll TAPF, Paulillo SM, Nebie I, Lanar DE, Corradin G, Burkhard P.

J Nanobiotechnology. 2017 Sep 6;15(1):62. doi: 10.1186/s12951-017-0295-0.

8.

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.

Laurens MB, Kouriba B, Bergmann-Leitner E, Angov E, Coulibaly D, Diarra I, Daou M, Niangaly A, Blackwelder WC, Wu Y, Cohen J, Ballou WR, Vekemans J, Lanar DE, Dutta S, Diggs C, Soisson L, Heppner DG, Doumbo OK, Plowe CV, Thera MA.

PLoS One. 2017 Mar 10;12(3):e0173294. doi: 10.1371/journal.pone.0173294. eCollection 2017.

9.

Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.

Seth L, Bingham Ferlez KM, Kaba SA, Musser DM, Emadi S, Matyas GR, Beck Z, Alving CR, Burkhard P, Lanar DE.

Vaccine. 2017 Oct 4;35(41):5448-5454. doi: 10.1016/j.vaccine.2017.02.040. Epub 2017 Mar 6.

10.

Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate.

Graves SF, Kouriba B, Diarra I, Daou M, Niangaly A, Coulibaly D, Keita Y, Laurens MB, Berry AA, Vekemans J, Ripley Ballou W, Lanar DE, Dutta S, Gray Heppner D, Soisson L, Diggs CL, Thera MA, Doumbo OK, Plowe CV, Sztein MB, Lyke KE.

Vaccine. 2016 May 17;34(23):2546-55. doi: 10.1016/j.vaccine.2016.04.019. Epub 2016 Apr 15.

PMID:
27087149
11.

Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort.

Dent AE, Malhotra I, Wang X, Babineau D, Yeo KT, Anderson T, Kimmel RJ, Angov E, Lanar DE, Narum D, Dutta S, Richards J, Beeson JG, Crabb BS, Cowman AF, Horii T, Muchiri E, Mungai PL, King CL, Kazura JW.

Clin Vaccine Immunol. 2015 Dec 9;23(2):104-16. doi: 10.1128/CVI.00452-15. Print 2016 Feb.

12.

Malaria vaccine based on self-assembling protein nanoparticles.

Burkhard P, Lanar DE.

Expert Rev Vaccines. 2015;14(12):1525-7. doi: 10.1586/14760584.2015.1096781. Epub 2015 Oct 15.

13.

Optimizing the design of protein nanoparticles as carriers for vaccine applications.

Doll TA, Neef T, Duong N, Lanar DE, Ringler P, Müller SA, Burkhard P.

Nanomedicine. 2015 Oct;11(7):1705-13. doi: 10.1016/j.nano.2015.05.003. Epub 2015 Jun 4.

14.

Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens.

Ondigo BN, Hodges JS, Ireland KF, Magak NG, Lanar DE, Dutta S, Narum DL, Park GS, Ofulla AV, John CC.

J Infect Dis. 2014 Oct 1;210(7):1123-32. doi: 10.1093/infdis/jiu225. Epub 2014 Apr 15. Erratum in: J Infect Dis. 2015 Oct 1;212(7):1175.

15.

Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice.

El Bissati K, Zhou Y, Dasgupta D, Cobb D, Dubey JP, Burkhard P, Lanar DE, McLeod R.

Vaccine. 2014 May 30;32(26):3243-8. doi: 10.1016/j.vaccine.2014.03.092. Epub 2014 Apr 13.

16.

Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.

Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Dube T, Soisson L, Diggs CL, House B, Bennett JW, Lanar DE, Dutta S, Heppner DG, Plowe CV, Doumbo OK.

PLoS One. 2013 Nov 18;8(11):e79323. doi: 10.1371/journal.pone.0079323. eCollection 2013.

17.

Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.

McCoy ME, Golden HE, Doll TA, Yang Y, Kaba SA, Zou X, Gerbasi VR, Burkhard P, Lanar DE.

Malar J. 2013 Apr 22;12:136. doi: 10.1186/1475-2875-12-136. Erratum in: Malar J. 2013;12:356. Zou, Xiaoyan [added]; Gerbasi, Vincent R [added].

18.

Expression, purification and refolding of a self-assembling protein nanoparticle (SAPN) malaria vaccine.

Guo Q, Dasgupta D, Doll TA, Burkhard P, Lanar DE.

Methods. 2013 May 1;60(3):242-7. doi: 10.1016/j.ymeth.2013.03.025. Epub 2013 Mar 30.

19.

Associations between antibodies to a panel of Plasmodium falciparum specific antigens and response to sub-optimal antimalarial therapy in Kampala, Uganda.

Keh CE, Jha AR, Nzarubara B, Lanar DE, Dutta S, Theisen M, Rosenthal PJ, Dorsey G, Nixon DF, Greenhouse B.

PLoS One. 2012;7(12):e52571. doi: 10.1371/journal.pone.0052571. Epub 2012 Dec 19.

20.

Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC, Freilich DA, Aguiar JC, Sacci JB Jr, Sedegah M, Nosek RA Jr, De La Vega P, Berzins MP, Majam VF, Abot EN, Ganeshan H, Richie NO, Banania JG, Baraceros MF, Geter TG, Mere R, Bebris L, Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, Hobart PM, Norman JA, Soisson LA, Hollingdale MR, Rogers WO, Doolan DL, Hoffman SL.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1564-84. doi: 10.4161/hv.22129. Epub 2012 Nov 1.

21.

Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.

Kaba SA, McCoy ME, Doll TA, Brando C, Guo Q, Dasgupta D, Yang Y, Mittelholzer C, Spaccapelo R, Crisanti A, Burkhard P, Lanar DE.

PLoS One. 2012;7(10):e48304. doi: 10.1371/journal.pone.0048304. Epub 2012 Oct 29.

22.

A field trial to assess a blood-stage malaria vaccine.

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV.

N Engl J Med. 2011 Sep 15;365(11):1004-13. doi: 10.1056/NEJMoa1008115.

23.

Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic.

Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, Lanar DE, Dutta S, Rosenthal PJ, Dorsey G, John CC.

J Infect Dis. 2011 Jul 1;204(1):19-26. doi: 10.1093/infdis/jir223.

24.

Plasmodium falciparum liver stage antigen-1 is cross-linked by tissue transglutaminase.

Nicoll WS, Sacci JB, Rodolfo C, Di Giacomo G, Piacentini M, Holland ZJ, Doerig C, Hollingdale MR, Lanar DE.

Malar J. 2011 Jan 21;10:14. doi: 10.1186/1475-2875-10-14.

25.

A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes.

Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, Griffith W, Lanar DE, Schwenk R, Krzych U, Cole RN, Sadegh-Nasseri S.

Nat Med. 2010 Nov;16(11):1333-40. doi: 10.1038/nm.2248. Epub 2010 Oct 31.

26.

Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study.

Asito AS, Piriou E, Odada PS, Fiore N, Middeldorp JM, Long C, Dutta S, Lanar DE, Jura WG, Ouma C, Otieno JA, Moormann AM, Rochford R.

Infect Agent Cancer. 2010 Jul 28;5:13. doi: 10.1186/1750-9378-5-13.

27.

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV.

PLoS One. 2010 Feb 4;5(2):e9041. doi: 10.1371/journal.pone.0009041.

28.

High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.

Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, Heppner DG, Lanar DE, Collins WE, Barnwell JW.

PLoS One. 2009 Dec 3;4(12):e8138. doi: 10.1371/journal.pone.0008138.

29.

A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.

Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE.

J Immunol. 2009 Dec 1;183(11):7268-77. doi: 10.4049/jimmunol.0901957. Epub 2009 Nov 13.

30.

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpetch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, Heppner DG, Miller RS.

Vaccine. 2009 Dec 11;28(2):452-62. doi: 10.1016/j.vaccine.2009.10.022. Epub 2009 Oct 24.

PMID:
19857448
31.

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.

Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr.

Vaccine. 2010 Jul 12;28(31):5135-44. doi: 10.1016/j.vaccine.2009.08.046. Epub 2009 Sep 6.

PMID:
19737527
32.

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr.

PLoS One. 2009;4(4):e5254. doi: 10.1371/journal.pone.0005254. Epub 2009 Apr 23.

33.

Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.

Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, Dutta S, Lanar DE, Heppner DG Jr, Doumbo OK, Plowe CV, Sztein MB.

Vaccine. 2009 Mar 26;27(15):2171-6. doi: 10.1016/j.vaccine.2009.01.097. Epub 2009 Jan 31.

34.

Effect of placental malaria and HIV infection on the antibody responses to Plasmodium falciparum in infants.

Ned RM, Price AE, Crawford SB, Ayisi JG, van Eijk AM, Otieno JA, Nahlen BL, Steketee RW, Slutsker L, Shi YP, Lanar DE, Udhayakumar V.

J Infect Dis. 2008 Dec 1;198(11):1609-19. doi: 10.1086/593066.

PMID:
18928377
35.

Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Noland GS, Hendel-Paterson B, Min XM, Moormann AM, Vulule JM, Narum DL, Lanar DE, Kazura JW, John CC.

Infect Immun. 2008 Dec;76(12):5721-8. doi: 10.1128/IAI.00591-08. Epub 2008 Sep 22.

36.

Polymorphism patterns in Duffy-binding protein among Thai Plasmodium vivax isolates.

Gosi P, Khusmith S, Khalambaheti T, Lanar DE, Schaecher KE, Fukuda MM, Miller SR.

Malar J. 2008 Jun 26;7:112. doi: 10.1186/1475-2875-7-112.

37.

Biochemical and immunological characterization of E. coli expressed 42 kDa fragment of Plasmodium vivax and P. cynomolgi bastianelli merozoite surface protein-1.

Kaushal DC, Kaushal NA, Narula A, Kumar N, Puri SK, Dutta S, Lanar DE.

Indian J Biochem Biophys. 2007 Dec;44(6):429-36.

PMID:
18320841
38.

Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K.

Infect Immun. 2008 May;76(5):2240-8. doi: 10.1128/IAI.01585-07. Epub 2008 Mar 3.

39.

Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW.

J Infect Dis. 2008 Feb 15;197(4):519-26. doi: 10.1086/526787.

40.

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial.

Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV.

PLoS One. 2008 Jan 23;3(1):e1465. doi: 10.1371/journal.pone.0001465.

41.

Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific.

Akpogheneta OJ, Duah NO, Tetteh KK, Dunyo S, Lanar DE, Pinder M, Conway DJ.

Infect Immun. 2008 Apr;76(4):1748-55. doi: 10.1128/IAI.01333-07. Epub 2008 Jan 22.

42.

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K.

Infect Immun. 2008 Apr;76(4):1709-18. doi: 10.1128/IAI.01614-07. Epub 2008 Jan 22.

43.

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Pichyangkul S, Kum-Arb U, Yongvanitchit K, Limsalakpetch A, Gettayacamin M, Lanar DE, Ware LA, Stewart VA, Heppner DG, Mettens P, Cohen JD, Ballou WR, Fukuda MM.

Infect Immun. 2008 Jan;76(1):229-38. Epub 2007 Oct 22.

44.

Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

Jiang G, Charoenvit Y, Moreno A, Baraceros MF, Banania G, Richie N, Abot S, Ganeshan H, Fallarme V, Patterson NB, Geall A, Weiss WR, Strobert E, Caro-Aquilar I, Lanar DE, Saul A, Martin LB, Gowda K, Morrissette CR, Kaslow DC, Carucci DJ, Galinski MR, Doolan DL.

Malar J. 2007 Oct 9;6:135.

45.

Structural basis of antigenic escape of a malaria vaccine candidate.

Dutta S, Lee SY, Batchelor AH, Lanar DE.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12488-93. Epub 2007 Jul 16.

46.
47.

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr.

Vaccine. 2007 May 22;25(21):4203-12. Epub 2007 Mar 26.

PMID:
17442466
48.

Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude.

Mlambo G, Mutambu SL, Mduluza T, Soko W, Mbedzi J, Chivenga J, Lanar DE, Singh S, Carucci D, Gemperli A, Kumar N.

Acta Trop. 2006 Nov;100(1-2):70-8. Epub 2006 Nov 17.

PMID:
17113021
49.

Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.

Brando C, Ware LA, Freyberger H, Kathcart A, Barbosa A, Cayphas S, Demoitie MA, Mettens P, Heppner DG, Lanar DE.

Infect Immun. 2007 Feb;75(2):838-45. Epub 2006 Nov 13.

50.

Malaria: therapy, genes and vaccines.

Chiang PK, Bujnicki JM, Su X, Lanar DE.

Curr Mol Med. 2006 May;6(3):309-26. Review.

PMID:
16712477

Supplemental Content

Loading ...
Support Center